Garetosmab clinical trials
Also written REGN2477.
How each study uses garetosmab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the garetosmab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Aug 2026 · PASATRU · BLA 761508 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2016 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses garetosmab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Not yet recruitingPhase 3Regeneron PharmaceuticalsNCT07559513Written as garetosmab
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT06299098Written as Garetosmab
- A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Active, not recruitingPhase 3Regeneron PharmaceuticalsNCT05394116Written as Garetosmab
- Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal WomenWithdrawnPhase 1Regeneron PharmaceuticalsNCT06970405Written as Garetosmab
- Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult MenCompletedPhase 1Regeneron PharmaceuticalsNCT02943239Written as REGN2477
- A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans ProgressivaCompletedPhase 2Regeneron PharmaceuticalsNCT03188666Written as REGN2477
- Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)WithdrawnPhase 3Regeneron PharmaceuticalsNCT04577820Written as garetosmab
- Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisWithdrawnPhase 2Regeneron PharmaceuticalsNCT03710941Written as REGN2477+REGN1033
- A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477CompletedPhase 1Regeneron PharmaceuticalsNCT02870400Written as REGN2477
Codes
What other systems call garetosmab · ClinicalTrials.gg INT017089
- UNII (FDA) KR9ZSKO5QEGARETOSMABOne source FDA
- NCI Thesaurus C170022GaretosmabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KR9ZSKO5QE | GARETOSMAB | One source FDA |
| NCI Thesaurus | C170022 | Garetosmab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.